The acting director of the FDA’s drug center, Tracy Beth Høeg, is departing the agency, according to STAT News. Her exit follows Commissioner Marty Makary’s resignation just days earlier, leaving the regulator with a widening leadership vacuum at a critical juncture.
Høeg’s departure compounds uncertainty at an agency already grappling with high-level turnover. The FDA oversees drug approvals, medical device reviews, and food safety—areas that now face potential delays or policy shifts without stable leadership.
The precise reasons for Høeg’s exit were not detailed in the report. No replacement has been announced for either her role or the commissioner position, according to the source.
Industry observers are watching for interim appointments and how the Biden administration will fill these posts. Drugmakers and patient groups alike depend on consistent regulatory guidance for clinical trials and market access.
Some analysts argue the departures may be routine in a transition period and could ultimately bring fresh perspective, though the lack of continuity risks slowing critical decisions.